Albert Bourla, Pfizer CEO (Markus Schreiber/AP Images)
January 30, 2024 07:32 AM ESTUpdated 08:03 AM
Pharma

Pfiz­er's Q4 rev­enue tum­bles 42% amid Covid re­set

Katherine Lewin

News Reporter

Pfiz­er round­ed out a tough year with fourth-quar­ter rev­enue of $14.2 bil­lion, a 42% de­crease com­pared to the same time in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times